AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31748467 — intervention group
Group type: COMPARATOR
Intervention: 10 mg ezetimibe daily
Number of subjects: 61
Study 31748467 — intervention group
Group type: COMPARATOR
Intervention: SC placebo Q4W
Number of subjects: 61
Study 31748467 — intervention group
Group type: COMPARATOR
Intervention: SC placebo Q2W
Number of subjects: 61
Study 30972995 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII combined with sitagliptin treatment (group C)
Number of subjects: 103
Study 30972995 — intervention group
Group type: EXPERIMENTAL
Intervention: CSII combined with acarbose treatment (group B)
Number of subjects: 103
Study 30972995 — intervention group
Group type: COMPARATOR
Intervention: CSII treatment alone (group A)
Number of subjects: 103
Study 28355090 — intervention group
Group type: EXPERIMENTAL
Intervention: TX-004HR (4-μg, 10-μg, and 25-μg doses)
Number of subjects: 0
Study 28355090 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26344671 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ) treatment, intravenous, open-label, assessed over the first 4 months (5 infusions).
Number of subjects: 610
Study 23537344 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR) for 8 weeks
Number of subjects: 48
Study 23537344 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (CTRL)
Number of subjects: 48
Study 21761206 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation using P6 acupoint for 30 min before spinal anesthesia (group III; n=150)
Number of subjects: 450
Study 21761206 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron 30 min before spinal anesthesia (group II; n=150)
Number of subjects: 450
Study 21761206 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group I; n=150)
Number of subjects: 450
Study 21761206 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment groups (II, III)
Number of subjects: 450
Study 18484458 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based session (40 minutes)
Number of subjects: 179
Study 18484458 — intervention group
Group type: COMPARATOR
Intervention: Lecture-based session (40 minutes)
Number of subjects: 179
Study 16488926 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-extraction time groups (10 s to 60 min)
Number of subjects: 500
Study 14966631 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole-chlorhexidine solution
Number of subjects: 202
Study 14966631 — intervention group
Group type: COMPARATOR
Intervention: Formocresol
Number of subjects: 202
Study 10798468 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction in the detection and management of urinary incontinence, educational materials for providers and patients, office system supports, and academic detailing.
Number of subjects: 668
Study 10798468 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly mentioned).
Number of subjects: 668
Study 8636175 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and bone grafting
Number of subjects: 120
Study 8636175 — intervention group
Group type: COMPARATOR
Intervention: Remanipulation and plaster
Number of subjects: 120
Study 8636175 — intervention group
Group type: COMPARATOR
Intervention: Closed external fixation with mobilisation
Number of subjects: 120
Study 8636175 — intervention group
Group type: COMPARATOR
Intervention: Closed external fixation without mobilisation
Number of subjects: 120
Study 1318281 — intervention group
Group type: EXPERIMENTAL
Intervention: ephedrine/caffeine combination (20mg/200mg)
Number of subjects: 180
Study 1318281 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 180
Study 1318281 — intervention group
Group type: COMPARATOR
Intervention: ephedrine (20 mg)
Number of subjects: 180
Study 1318281 — intervention group
Group type: COMPARATOR
Intervention: caffeine (200 mg)
Number of subjects: 180
Study 6469401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 6469401 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal test
Number of subjects: 103
Study 31331803 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery applied perioperatively (once preoperatively, once on the first postoperative day, twice on the second and third days, totaling six applications)
Number of subjects: 0
Study 31331803 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided imagery applied perioperatively
Number of subjects: 0
Study 31331803 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment and nursing care
Number of subjects: 0
Study 29870922 — intervention group
Group type: EXPERIMENTAL
Intervention: Capacitive-resistive electric transfer therapy (Tecar)
Number of subjects: 14
Study 29870922 — intervention group
Group type: COMPARATOR
Intervention: Passive rest (Control)
Number of subjects: 14
Study 26963316 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 0
Study 26963316 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 0
Study 25130297 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 750 mg IV for 5 days
Number of subjects: 241
Study 25130297 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 500 mg IV for 7-14 days
Number of subjects: 241
Study 22443460 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI at hospitals without on-site cardiac surgery
Number of subjects: 18867
Study 22443460 — intervention group
Group type: COMPARATOR
Intervention: PCI at hospitals with on-site cardiac surgery
Number of subjects: 18867
Study 21218756 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs)
Number of subjects: 380
Study 18669898 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular coiling (EVT)
Number of subjects: 278
Study 18669898 — intervention group
Group type: COMPARATOR
Intervention: Neurosurgical clipping (NST)
Number of subjects: 278
Study 15899100 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 100 mg od
Number of subjects: 0
Study 15899100 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumiracoxib 100 mg od with loading dose of 200 mg od for the first two weeks
Number of subjects: 0
Study 15899100 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg od
Number of subjects: 0
Study 15899100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11840406 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative exercise (strength activities)
Number of subjects: 0
Study 11840406 — intervention group
Group type: COMPARATOR
Intervention: Anesthesia or analgesia
Number of subjects: 0
Study 10086760 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative treatment by primary care physicians (PCPs) and mental health providers (MHPs)
Number of subjects: 162
Study 10086760 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact with co-treating MHPs
Number of subjects: 162
Study 10086760 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-location of MHP and PCP practices
Number of subjects: 162
Study 10086760 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed care programs
Number of subjects: 162
Study 7670605 — intervention group
Group type: EXPERIMENTAL
Intervention: Hollister Colostomy Adhesive with Silastic Medical Adhesive A
Number of subjects: 25
Study 7670605 — intervention group
Group type: EXPERIMENTAL
Intervention: Hollister Colostomy Adhesive with Silastic MDX 4‐4210
Number of subjects: 25
Study 7670605 — intervention group
Group type: EXPERIMENTAL
Intervention: Pros‐Aide Adhesive with Silastic MDX 4‐4210
Number of subjects: 25
Study 7670605 — intervention group
Group type: EXPERIMENTAL
Intervention: Pros‐Aide Adhesive with Silicone A‐2186
Number of subjects: 25
Study 7670605 — intervention group
Group type: EXPERIMENTAL
Intervention: Pros‐Aide Adhesive with Silastic Medical Adhesive A
Number of subjects: 25
Study 2124982 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid
Number of subjects: 10
Study 383417 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP therapy (10 patients)
Number of subjects: 24
Study 383417 — intervention group
Group type: COMPARATOR
Intervention: No PEEP (14 patients)
Number of subjects: 24
Study 30963555 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia
Number of subjects: 11208
Study 30963555 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural analgesia
Number of subjects: 11208
Study 30963555 — intervention group
Group type: COMPARATOR
Intervention: Volatile anaesthesia
Number of subjects: 11208
Study 30963555 — intervention group
Group type: COMPARATOR
Intervention: Paravertebral analgesia
Number of subjects: 11208
Study 29911826 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive information (Group A)
Number of subjects: 0
Study 29911826 — intervention group
Group type: COMPARATOR
Intervention: No supportive information (Group B)
Number of subjects: 0
Study 26140739 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (300 mg/dL)
Number of subjects: 150
Study 26140739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 23823904 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigation (PN) intervention
Number of subjects: 181
Study 23823904 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 181
Study 23823904 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of OCR
Number of subjects: 181
Study 23823904 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital status (married)
Number of subjects: 181
Study 21134995 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin therapy (20 mg/day, group Ia, n = 15)
Number of subjects: 60
Study 21134995 — intervention group
Group type: COMPARATOR
Intervention: Hypolipidemic diet therapy (group Ib, n = 15)
Number of subjects: 60
Study 21134995 — intervention group
Group type: COMPARATOR
Intervention: Normolipidemic patients (group II, n = 30)
Number of subjects: 60
Study 19034106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tariquidar (150 mg)
Number of subjects: 9
Study 19034106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 16310974 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus contingency management (CM)
Number of subjects: 115
Study 16310974 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 115
Study 16310974 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment plus CM
Number of subjects: 115
Study 16310974 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-treatment motivation
Number of subjects: 115
Study 12749496 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (ITNs)
Number of subjects: 0
Study 12749496 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational activities prior to distribution
Number of subjects: 0
Study 12749496 — intervention group
Group type: EXPERIMENTAL
Intervention: Community perceptions about ITNs
Number of subjects: 0
Study 10938184 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroquinidine (450 mg/day)
Number of subjects: 10
Study 10938184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1590680 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefprozil (500 mg every 12 h for 8 days)
Number of subjects: 12
Study 1590680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3844036 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated 3-g doses of amoxycillin
Number of subjects: 20
Study 3844036 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 3-g dose of amoxycillin
Number of subjects: 20
Study 3844036 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 20
Study 30706097 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH, 20 mg)
Number of subjects: 24
Study 30706097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 30264159 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading doses of atorvastatin (80 mg) administered before and 24 hours after PCI.
Number of subjects: 4191
Study 30264159 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading doses of atorvastatin (80 mg) administered less than 12 hours before PCI.
Number of subjects: 4191
Study 30264159 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading doses of atorvastatin (80 mg) in patients with ST-segment elevation myocardial infarction (STEMI).
Number of subjects: 4191
Study 30264159 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading doses of atorvastatin (80 mg) in patients with non-ST-segment elevation ACS.
Number of subjects: 4191
Study 27145825 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol + ivabradine (group II)
Number of subjects: 100
Study 27145825 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol only (group I)
Number of subjects: 100
Study 23735746 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 200 mg/100 mg
Number of subjects: 1064
Study 23735746 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 400 mg/200 mg
Number of subjects: 1064
Study 23735746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1064
Study 22188546 — intervention group
Group type: EXPERIMENTAL
Intervention: Affectively hot condition (blood donation paraphernalia)
Number of subjects: 76
Study 22188546 — intervention group
Group type: COMPARATOR
Intervention: Cold condition (control)
Number of subjects: 76
Study 19732237 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary vein antrum isolation (PVAI) only
Number of subjects: 320
Study 19732237 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein antrum isolation (PVAI) and superior vena cava isolation (SVCI)
Number of subjects: 320
Study 18614871 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose nevirapine (sdNVP)
Number of subjects: 0
Study 18614871 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine (ZDV)
Number of subjects: 0
Study 18614871 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination ZDV/sdNVP
Number of subjects: 0
Study 18614871 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course highly active antiretroviral therapy (HAART)
Number of subjects: 0
Study 18614871 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 0
Study 18614871 — intervention group
Group type: COMPARATOR
Intervention: ZDV
Number of subjects: 0
Study 16143787 — intervention group
Group type: EXPERIMENTAL
Intervention: IMCBT plus 3DCRT
Number of subjects: 0
Study 16143787 — intervention group
Group type: COMPARATOR
Intervention: IMRT
Number of subjects: 0
Study 12171813 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of emotional scale scores on the SOLDQ
Number of subjects: 3282
Study 12171813 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of physical scale scores on the SOLDQ
Number of subjects: 3282
Study 12171813 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of coping skills scale scores on the SOLDQ
Number of subjects: 3282
Study 12171813 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest quartile of physical function scores on the SOLDQ
Number of subjects: 3282
Study 10188712 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0
Study 10188712 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0
Study 10188712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9005419 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women with LH
Number of subjects: 0
Study 9005419 — intervention group
Group type: COMPARATOR
Intervention: Healthy pregnant women
Number of subjects: 0
Study 2072371 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate meal
Number of subjects: 8
Study 2072371 — intervention group
Group type: COMPARATOR
Intervention: No meal
Number of subjects: 8
Study 6345428 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (300 mg daily)
Number of subjects: 40
Study 6345428 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac (200 mg daily)
Number of subjects: 40
Study 30924412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-foot orthoses (AFO)
Number of subjects: 15
Study 30924412 — intervention group
Group type: COMPARATOR
Intervention: Historical control group (advice to walk at home)
Number of subjects: 15
Study 30272850 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised nutrition education with customised dishware and food supplements (mixed nuts and skimmed milk powder)
Number of subjects: 36
Study 30272850 — intervention group
Group type: COMPARATOR
Intervention: Multiple micronutrient supplements
Number of subjects: 36
Study 30272850 — intervention group
Group type: COMPARATOR
Intervention: Multiple micronutrients plus isolated soy protein supplement
Number of subjects: 36
Study 30272850 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 26573239 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly filled flowable composite G-aenial Universal Flo
Number of subjects: 32
Study 26573239 — intervention group
Group type: COMPARATOR
Intervention: Conventional composite Estelite Sigma Quick
Number of subjects: 32
Study 25194782 — intervention group
Group type: EXPERIMENTAL
Intervention: lithium plus optimal personalized treatment (OPT)
Number of subjects: 283
Study 25194782 — intervention group
Group type: COMPARATOR
Intervention: optimal personalized treatment (OPT) alone
Number of subjects: 283
Study 22155037 — intervention group
Group type: EXPERIMENTAL
Intervention: Proanthocyanidin (PA) 1.0wt%
Number of subjects: 40
Study 22155037 — intervention group
Group type: EXPERIMENTAL
Intervention: Proanthocyanidin (PA) 2.0wt%
Number of subjects: 40
Study 22155037 — intervention group
Group type: EXPERIMENTAL
Intervention: Proanthocyanidin (PA) 3.0wt%
Number of subjects: 40
Study 22155037 — intervention group
Group type: COMPARATOR
Intervention: PA-free adhesive (Control)
Number of subjects: 40
Study 21098206 — intervention group
Group type: COMPARATOR
Intervention: Pneumatic dilation (group A, n = 30)
Number of subjects: 120
Study 21098206 — intervention group
Group type: COMPARATOR
Intervention: Temporary self-expanding metallic stent (20 mm, group B, n = 30)
Number of subjects: 120
Study 21098206 — intervention group
Group type: COMPARATOR
Intervention: Temporary self-expanding metallic stent (25 mm, group C, n = 30)
Number of subjects: 120
Study 21098206 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary self-expanding metallic stent (30 mm, group D, n = 30)
Number of subjects: 120
Study 17390202 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 59
Study 17390202 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT-4)
Number of subjects: 59
Study 17390202 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 59
Study 16338914 — intervention group
Group type: EXPERIMENTAL
Intervention: DynaMed (A)
Number of subjects: 52
Study 16338914 — intervention group
Group type: COMPARATOR
Intervention: Control (N)
Number of subjects: 52
Study 12221218 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylloquinone-fortified oil (377 +/- 46 micro g/d)
Number of subjects: 36
Study 12221218 — intervention group
Group type: COMPARATOR
Intervention: Broccoli diet (417 +/- 45 micro g/d)
Number of subjects: 36
Study 12221218 — intervention group
Group type: EXPERIMENTAL
Intervention: Phylloquinone-fortified oil
Number of subjects: 36
Study 12221218 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 36
Study 10457877 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous spinal anaesthesia (1 mL bolus of bupivacaine 0.25% followed by continuous infusion of 10 mL over 24 h)
Number of subjects: 102
Study 10457877 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural anaesthesia (10 mL bolus of bupivacaine 0.25% followed by 2 mL h-1)
Number of subjects: 102
Study 10457877 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous spinal anaesthesia
Number of subjects: 102
Study 10457877 — intervention group
Group type: COMPARATOR
Intervention: Continuous epidural anaesthesia
Number of subjects: 102
Study 7872388 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aldose reductase inhibitor (CT-112)
Number of subjects: 39
Study 7872388 — intervention group
Group type: COMPARATOR
Intervention: Control group (same preparation without the inhibitor)
Number of subjects: 39
Study 2010880 — intervention group
Group type: EXPERIMENTAL
Intervention: Poet condition (authorial intentions)
Number of subjects: 0
Study 2010880 — intervention group
Group type: COMPARATOR
Intervention: Computer condition (no authorial intentions)
Number of subjects: 0
Study 6275788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 125 mg
Number of subjects: 45
Study 6275788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 250 mg
Number of subjects: 45
Study 6275788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 500 mg
Number of subjects: 45
Study 6275788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (all doses)
Number of subjects: 45
Study 31845845 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning model for predicting enhancing lesions on unenhanced MRI scans.
Number of subjects: 1008
Study 30003336 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release β-alanine (SR)
Number of subjects: 39
Study 30003336 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid-release β-alanine (RR)
Number of subjects: 39
Study 30003336 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 39
Study 28218406 — intervention group
Group type: EXPERIMENTAL
Intervention: Glue (Histoacryl®)
Number of subjects: 370
Study 28218406 — intervention group
Group type: COMPARATOR
Intervention: Sutures (non-absorbable polypropylene)
Number of subjects: 370
Study 25488303 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestipitant (4-36 mg)
Number of subjects: 130
Study 25488303 — intervention group
Group type: COMPARATOR
Intervention: Ondansetron (4 mg)
Number of subjects: 130
Study 23802771 — intervention group
Group type: EXPERIMENTAL
Intervention: IFC 1 kHz
Number of subjects: 150
Study 23802771 — intervention group
Group type: EXPERIMENTAL
Intervention: IFC 4 kHz
Number of subjects: 150
Study 23802771 — intervention group
Group type: COMPARATOR
Intervention: Placebo IFC
Number of subjects: 150
Study 22101886 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg DHA and 42 mg EPA daily for 3 weeks
Number of subjects: 120
Study 22101886 — intervention group
Group type: COMPARATOR
Intervention: Without DHA
Number of subjects: 120